QuickSummary: Will be RXI-109 the winner to reduce dermal scarring?

* wall-street.cz is not responsible for the content in this press release. $RXIID $RXII  Don’t forget, that RXI-109 is the specific clinical candidate to reduce dermal scarring and the results are seen immediately. We will not have to wait to the end Phase2. + Dr.Frost Majority Holder (Opko Health (OPK) + very positive data from Phase …

Continue reading ‘QuickSummary: Will be RXI-109 the winner to reduce dermal scarring?’ »